Drug Combination Details
| General Information of the Combination (ID: C71193) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Cetuximab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | POLR2A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| UM-SCC-6 | CVCL_7773 | Tongue squamous cell carcinoma | Homo sapiens | |||
| NCI-H520 | CVCL_1566 | Lung squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Cetuximab-Triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II. Mol Ther Oncolytics. 2020 Jul 6;18:304-316. | |||
